OneBlood

OneBlood is primarily an operating healthcare enterprise structured as a 501(c)(3) non-profit. It collects, tests, manufactures, and distributes blood and biologics to hospitals, generating revenue from those services rather than distributing grants from an endowment. The organization does maintain a separate OneBlood Foundation for philanthropic activities, but the core entity functions as a vertically integrated biologics supplier, not a classic private foundation.

The portfolio's mandate is shaped by extreme liquidity and working-capital demands tied to an essential healthcare supply chain. Unlike a university endowment that targets 5% annual spending from a perpetual pool, OneBlood must ensure it can fund testing, manufacturing, and fleet logistics through demand surges caused by hurricanes or mass-casualty events. This likely produces an allocation heavier in short-duration fixed income and highly liquid assets than a standard 60/40 endowment model.

Ultimate fiduciary responsibility sits with the Board of Directors, chaired by Michael De Lucca, with CFO John Murphy overseeing treasury and financial operations. The organization's investment governance structure — whether managed by an internal committee, an outsourced chief investment officer, or external managers — is not publicly detailed. Given the scale of operations, it likely relies on professional external advisors for asset allocation and manager selection.

OneBlood operates donor centers, mobile blood drives, and hospital service logistics across five states: Florida, Georgia, Alabama, North Carolina, and South Carolina. Its corporate headquarters and a biologics manufacturing facility are located in Orlando, Florida. This makes it the dominant blood product supplier for the southeastern US, a region subject to hurricane seasons that repeatedly test the organization's disaster-readiness and inventory management.

There is no evidence OneBlood engages in private equity, venture capital, or direct company investments. The investment portfolio almost certainly holds traditional marketable securities — public equities, government bonds, and corporate credit facilities — chosen for daily liquidity and capital preservation. The organization's core capital allocation is to its own physical infrastructure: refrigerated logistics, manufacturing facilities, and the Big Red Bus donor fleet.

The OneBlood Foundation, Inc. is a separate philanthropic arm that extends the organization's mission beyond clinical logistics. It typically raises funds to support blood donation education, donor recognition, and patient-assistance programs. Structurally, it operates as a distinct legal entity, though leadership overlaps with the main OneBlood organization.

OneBlood processes roughly one million whole-blood and apheresis donations annually, placing it among the largest independent blood centers in the United States. It is not the American Red Cross — the nation's dominant supplier — but it is a consolidated regional giant formed from multiple legacy blood banks, giving it significant market density in the Southeast that few other single-state or two-state operators can match.